Infarktbedingter kardiogener Schock

Abstract

In patients admitted with acute myocardial infarction, cardiogenic shock remains the most common cause of death. Multidisciplinary care in a specialized center and guideline-compliant treatment of cardiogenic shock are crucial for the survival and prognosis of affected patients. Hemodynamic monitoring and stabilization by volume expansion, vasopressors and inotropes represent initial steps in the management of patients with cardiogenic shock. Nevertheless, early revascularization of the culprit-lesion is proved to be the most important treatment modality. Although the use of active mechanical circulatory support appears to be a promising therapeutic concept to improve clinical outcome in patients with infarct-related cardiogenic shock, in the few previous randomized trials mechanical circulatory support failed to show beneficial effects on short-term and long-term survival.

Der kardiogene Schock ist die häufigste Todesursache bei Patienten mit akutem Myokardinfarkt im Krankenhaus. Ein frühzeitiges Erkennen und die rasche Leitlinien-konforme Therapie sind Prognose-entscheidend; dabei ist neben der Basistherapie die unverzügliche Revaskularisierung der „Culprit“-Läsion anzustreben. Welche Rolle eine mechanische Kreislaufunterstützung bei Patienten mit kardiogenem Schock spielt, ist noch unklar.

Schlüsselwörter

kardiogener Schock - akuter Myokardinfarkt - Revaskularisation - Prognose - mechanische Kreislaufunterstützung

Key words

cardiogenic shock - acute myocardial infarction - revascularization - prognosis - mechanical circulatory support

Publication History

Article published online:
29 April 2020

• Literatur

• 1 van Diepen S, Katz JN, Albert NM. et al Contemporary management of cardiogenic shock – a scientific statement. Circulation 2017; 136: e232-e268 . doi:10.1161/CIR.0000000000000525
• 2 Thiele H, Ohman EM, de Waha-Thiele S. et al Management of cardiogenic shock complicating myocardial infarction: an update 2019. Eur Heart J 2019; 40: 2671-2683 . doi:10.1093/eurheartj/ehz363
• 3 Rathod KS, Koganti S, Iqbal MB. et al Contemporary trends in cardiogenic shock: Incidence, intra-aortic balloon pump utilisation and outcomes from the London Heart Attack Group. Eur Heart J Acute Cardiovasc Care 2018; 7: 16-27 . doi:10.1177/2048872617741735
• 4 Thiele H, Akin I, Sandri M. et al PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med 2017; 377: 2419-2432 . doi:10.1056/NEJMoa1710261
• 5 Thiele H, Allam B, Chatellier G. et al Shock in acute myocardial infarction: the Cape Horn for trials?. Eur Heart J 2010; 31: 1828-1835 . doi:10.1093/eurheartj/ehq220
• 6 Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003; 107: 2998-3002 . doi:10.1161/01.CIR.0000075927.67673
• 7 Thiele H. Cardiogenic shock: Current evidence. Herz 2017; 42: 795-806 . doi:10.1007/s00059-017-4619-5
• 8 Mebazaa A, Combes A, van Diepen S. et al Management of cardiogenic shock complicating myocardial infarction. Intensive Care Med 2018; 44: 760-773 . doi:10.1007/s00134-018-5214-9
• 9 Jentzer JC, van Diepen S, Barsness GW. et al Cardiogenic Shock Classification to Predict Mortality in the Cardiac Intensive Care Unit. J Am Coll Cardiol 2019; 74: 2117-2128 . doi:10.1016/j.jacc.2019.07.077
• 10 Thiele H, Zeymer U, Neumann FJ. et al Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367: 1287-1296 . doi:10.1056/NEJMoa1208410
• 11 De Backer D, Biston P, Devriendt J. et al Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362: 779-789 . doi:10.1056/NEJMoa0907118
• 12 Mebazaa A, Nieminen MS, Packer M. et al Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297: 1883-1891 . doi:10.1001/jama.297.17.1883
• 13 Cholley B, Caruba T, Grosjean S. et al Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass. JAMA 2017; 318: 548-556 . doi:10.1001/jama.2017.9973
• 14 Mehta RH, Leimberger JD, van Diepen S. LEVO-CTS Investigators. et al Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. N Engl J Med 2017; 376: 2032-2042 . doi:10.1056/NEJMoa1616218
• 15 Gordon AC, Perkins GD, Singer M. et al Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. N Engl J Med 2016; 375: 1638-1648 . doi:10.1056/NEJMoa1609409
• 16 Felker GM, Benza RL, Chandler AB. et al Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41: 997-1003 . doi:10.1016/s0735-1097(02)02968-6
• 17 van Diepen S, Reynolds HR, Stebbins A. et al Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. Crit Care Med 2014; 42: 281-288 . doi:10.1097/CCM.0b013e31829f6242
• 18 Ibanez B, James S, Agewall S. ESC Scientific Document Group. et al 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018; 39: 119-177 . doi:10.1093/eurheartj/ehx393
• 19 Hochman JS, Sleeper L, Webb JG. et al Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295: 2511-2515 . doi:10.1001/jama.295.21.2511
• 20 Thiele H, Akin I, Sandri M. . CULPRIT-SHOCK Investigators. et al One-Year Outcomes after PCI Strategies in Cardiogenic Shock. N Engl J Med 2018; 379: 1699-1710 . doi:10.1056/NEJMoa1808788
• 21 Ledwoch J, Fuernau G, Desch S. et al Drug-eluting stents versus bare-metal stents in acute myocardial infarction with cardiogenic shock. Heart 2017; 103: 1177-1184 . doi:10.1136/heartjnl-2016-310403
• 22 Pancholy SB, Palamaner Subash Shantha G, Romagnoli E. et al Impact of access site choice on outcomes of patients with cardiogenic shock undergoing percutaneous coronary intervention. Am Heart J 2015; 170: 353-361 . doi:10.1016/j.ahj.2015.05.001
• 23 Orban M, Limbourg T, Neumann FJ. et al ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis. EuroIntervention 2016; 12: e1395-e1403 . doi:10.4244/EIJY15M12_04
• 24 Tousek P, Rokyta R, Tesarova J. et al Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock. Acute Card Care 2011; 13: 116-122 . doi:10.3109/17482941.2011.567282
• 25 Steg PG, James SK, Atar D. et al ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619 . doi:10.1093/eurheart/ehs215
• 26 Prondzinsky R, Unverzagt S, Russ M. et al Hemodynamic effects of intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock. Shock 2012; 37: 378-384 . doi:10.1097/SHK.0b013e31824a67af
• 27 Thiele H, Zeymer U, Neumann FJ. et al Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 2013; 382: 1638-1645 . doi:10.1016/S0140-6736(13)61783-3
• 28 Thiele H, Zeymer U, Thelemann N. et al Intra-aortic balloon pump in cardiogenic shock complicating acute myocardial infarction: long-term 6-year outcome of the randomized IABPSHOCK II trial. Circulation 2019; 139: 395-403 . doi:10.1161/CIRCULATIONAHA.118.038201
• 29 Thiele H, Jobs A, Ouweneel DM. et al Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J 2017; 38: 3523-3531 . doi:10.1093/eurheartj/ehx363
• 30 Schrage B, Ibrahim K, Loehn T. et al Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. Circulation 2019; 139: 1249-1258 . doi:10.1161/CIRCULATIONAHA.118.036614
• 31 Amin AP, Spertus JA, Curtis JP. et al The Evolving Landscape of Impella^® Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention with Mechanical Circulatory Support. Circulation 2019; 141: 273-284 . doi:10.1161/CIRCULATIONAHA.119.044007
• 32 Koeckert MS, Jorde U, Naka Y. et al Impella LP 2.5 for left ventricular unloading during venoarterial extracorporeal membrane oxygenation support. J Card Surg 2011; 26: 666-668 . doi:10.1111/j.1540-8191.2011.01338
• 33 Ouweneel DM, Schotborgh J, Limpens J. et al Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med 2016; 42: 1922-1934 . doi:10.1007/s00134-016-4536-8
• 34 Beurtheret S, Mordant P, Paoletti X. et al Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program). Eur Heart J 2013; 34: 112-120 . doi:10.1093/eurheartj/ehs081
• 35 Brunner S, Guenther SPW, Lackermair K. et al Extracorporeal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction. J Am Coll Cardiol 2019; 73: 2355-2357 . doi:10.1016/j.jacc.2019.02.044
• 36 de Waha S, Graf T, Desch S. et al Outcome of elderly undergoing extracorporeal life support in refractory cardiogenic shock. Clin Res Cardiol 2017; 106: 379-385 . doi:10.1007/s00392-016-1068-8